Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805346 · ClinicalTrials.gov registry record · NA
Remote Ischemic Conditioning in Oncology
A NA study of Participants Undergoing Anthracycline Chemotherapy, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT04805346: Completed NA study of Participants Undergoing Anthracycline Chemotherapy, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04805346 is a NA study of Participants Undergoing Anthracycline Chemotherapy that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04805346, a NA study of Participants Undergoing Anthracycline Chemotherapy, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic conditioning (RIC) is feasible in children and young adults receiving anthracycline chemotherapy. The secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive RIC prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.
Primary Outcome
Patients with intra-thoracic disease may also receive consolidative radiation that includes portions of the myocardium within the radiation field and thus further increase their risk of developing therapy-related cardiomyopathy. Thus, the development of cardioprotective strategies during therapy for these malignancies is of primary interest to minimize the potential late adverse effects of anthracyclines among the long term survivors of these conditions.
Conditions Studied
Interventions
- DEVICE autoRIC®
Study Locations (1)
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2024-05-03 |
| Phase | NA |
What the finished NCT04805346 record still lists
NCT04805346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Participants Undergoing Anthracycline Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which autoRIC® is the first listed.
NCT04805346 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04805346 about?
NCT04805346 is a clinical study titled "Remote Ischemic Conditioning in Oncology". This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study ...
What is the current status of trial NCT04805346?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2021-04-30. Estimated completion is 2024-05-03.
What conditions does trial NCT04805346 study?
This clinical trial studies the following conditions: Participants Undergoing Anthracycline Chemotherapy.
What interventions are being tested in trial NCT04805346?
The interventions under investigation include: autoRIC® (DEVICE).
Who is sponsoring clinical trial NCT04805346?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04805346 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04805346's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI